Natco Pharma share price falls 5% on setback in US patent litigation
Natco and partner Alvogen are reviewing the order and will evaluate all options to appeal the judgment, the pharma firm has said20-08-2021
20-08-2021
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Disclosure under Regulation 30 of SEBI (LODR) Regulations 201520-08-2021
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter ended June 30, 202118-08-2021
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
copy of News paper publications13-08-2021
Natco Pharma Ltd - 524816 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations 201513-08-2021
Natco Pharma Ltd - 524816 - Fixes Record Date for Interim Dividend
Natco Pharma Ltd has informed BSE that the Company has fixed August 25, 2021 as the Record Date for the purpose of Payment of Interim Dividend.The payment of said interim dividend will be paid from August 31, 2021.13-08-2021
Earnings Call for Q1FY22 of Natco Pharma
Conference Call with Natco Pharma Management and Analysts on Q1FY22 Performance and Outlook. Listen to the full earnings transcript.12-08-2021
Natco Pharma Q1 results: Net falls 39% to Rs 75 cr
The company had posted a net profit of Rs 122.1 crore for the corresponding period of the previous fiscal, Natco Pharma said in regulatory filing12-08-2021
Q1FY22 Result Announced for Natco Pharma Ltd.
NATCO records INR 427.30 Crore consolidated revenue and INR 75 Crore of profit, after tax, for the first quarter ended 30th June 2021 NATCO Pharma Limited has recorded consolidated total revenue of INR 427.30 Crore for the quarter ended on 30th June 2021 as against INR 582.10 crores for Q1, FY 2020. The net profit after tax for the period, on a consolidated basis, was INR 75 Crore as against INR 122.10 crores for same quarter in the last financial year. The degrowth in sales can be partially attributed to the higher proportion of initial phase of pandemic exports to USA in Chloroquine Phosphate tablets and Oseltamivir Phosphate capsules in the revenues for the quarter ended 30th June 2020. The pandemic continues to impact the revenues of the company but recovered compared to quarter ending March 2021. The Company has strong product launches both in Export markets and domestic India business during the current financial year and expects to have good growth. The Board of Directors has recommended an interim dividend of INR 2.0 per equity share of INR 2.0 each, during the First Quarter of FY 2021-22. Result PDF12-08-2021
NATCO PHARMA LTD. - 524816 - Corporate Action-Board approves Dividend
Declared an Interim Dividend of Rs.2/- each for the Financial year 2021-2212-08-2021